GSK inks tech licensing pact with DNA manufacturer Elegen to bolster R&D efforts

24 Jan 2024
www.fiercepharma.com
AcquisitionLicense out/inGene Therapy
GSK inks tech licensing pact with DNA manufacturer Elegen to bolster R&D efforts
Preview
Source: FiercePharma
As the pharma giant works to develop new vaccines and treatments, GSK inked a partnership with Elegen to leverage the latter company's proprietary DNA manufacturing technology.
Pharma giant GSK and venture capital-backed Elegen are partnering to leverage the DNA manufacturer's proprietary technology to help develop new vaccines and medicines.
Under the deal, Elegen could net up to $35 million in "near-term financial and development support and fees," plus additional revenues related to sales of its Enfinia DNA, the company said in a release. Further, there's a chance GSK could take an equity investment in the California-based DNA specialist, according to the release.
Elegen launched its Enfinia DNA product last March. It can deliver high-complexity, clonal-quality, linear DNA as quickly as within 7 business days, according to the company.
DNA produced by the platform is cell-free and has the potential to enable a seamless transition from discovery to clinical scale-up, the company said.
“Over the past year dozens of customers, including multiple top 10 biopharma, have validated the unprecedented speed, length, accuracy and complexity of our cell-free DNA manufacturing technology,” Matthew Hill, Elegen's founder and chief executive, said in a Wednesday release. “This collaboration will expand our offering to include the clinical production of genetic medicines potentially including mRNA, cell and viral gene therapies.”
Founded in 2017, Elegen's backers include a16z, Y Combinator and KdT Ventures.
Elsewhere in the DNA manufacturing field, Moderna this month shelled out $85 million to snap up Japanese DNA supplier OriCiro Genomics K.K. It marked Moderna’s first acquisition since launching in 2010. At the time, Moderna CEO Stéphane Bancel told Fierce that the purchase provided a critical upgrade to Moderna's clinical development process.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.